Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten FDA-approved ophthalmic pharmaceutical products. Harrow also owns and operates ImprimisRx, the leading U.S. ophthalmic‑focused pharmaceutical compounding business, which also serves as a mail-order pharmacy licensed to ship prescription medications in all 50 states. Harrow has non-controlling equity positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc., companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in four late-stage drug candidates being developed by Surface and Melt.

Manufacturing

Pharmaceutical

Harrow

Mark L. Baum

Garrett S.

Mark Mannebach

Kim Barratt

Dennis E. Saadeh

Andrew R. Boll

John P. Saharek

Sales and Marketing

Leadership Team

Harrow

Org chart

Teams

Sales and Marketing

Leadership Team

Similar companies